BioSpace News Archive

The CHMP adopted a positive opinion based on results from the pivotal Phase 2 KarMMa study evaluating the efficacy and safety of Abecma in 128 patients with heavily pre-treated and highly refractory multiple myeloma.

Ampersand Capital Partners announced that it has completed the sale of Nexcelom Bioscience, one of its portfolio companies and a leading provider of automated cell counting solutions, to PerkinElmer for $260 million in cash.

InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that China’s National Medical Products Administration has approved the initiation of a Phase I clinical trial of ICP-033, the Company’s novel RTK inhibitor and its sixth innovative drug to enter clinical development.

Evaxion Biotech A/S, a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced the acceptance of a new scientific paper by the International Conference on Machine Learning.

European Commission Decision expected Q3 2021 Temporary Authorization for Use (ATU) Granted in France to Allow Access and Reimbursement of Vosoritide to Begin Immediately

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today there will be a symposium highlighting sotagliflozin followed by a live video question and answer period during the American Diabetes Association’s 81 st Scientific Sessions being held virtually June 25, 2021 through June 29, 2021: Tuesday, June 29, 2021, 10:15 am – 12:15 pm ET

I-Mab today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application to initiate a phase 1b trial of felzartamab, a CD38 antibody, in patients with systemic lupus erythematosus (SLE).

Curis, Inc. today announced that it will be added to the Russell 2000®, 3000® and Microcap® indexes at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the U.S. market opens on June 4, 2021.

SureCo, a leader in pioneering health care solutions, purchases telemedicine network and platform, Tembi Health

OcuTerra Therapeutics, Inc . today announced the appointment of David J. Tanzer, MD, as Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs.